Isolated peptides that include one or more antigenic sites of Zika virus (ZIKV) and methods of their use and production are disclosed. The peptides can be used, for example, to detect exposure of a subject to a flavivirus infection, such as a ZIKV infection.

The present disclosure relates to polypeptides that specifically bind to Dengue virus non-structural protein 1, including antibodies and fragments thereof. The antibody or antigen-binding fragment thereof may specifically bind Dengue virus (DENV) serotype 4 and include: a heavy chain variable region that comprises at least one CDR amino acid sequence selected from the group consisting of: SGYNWH, YIHYSGGTNYNPSLKS, RTGTVPFAY, SYVMH, YLNPYNDDTKYNEKFKG, and GPPYALDY. The present disclosure further relates to methods of producing the polypeptides of the present disclosure, methods of diagnosing DENV, and methods of treating a DENV infection.

Molecules, test kits, test kit components and methods for detecting and measuring different first and second antibodies in a test sample using a single test are provided herein. A method includes the steps of obtaining the test specimen from a subject, transferring the test specimen to a sample receiving portion of an assay of a test kit, and reading the results from the assay. The test kit includes a first molecule comprising a first portion of a protein, wherein the first antibody has a first affinity to bind to the first portion, and a second molecule comprising a second portion of the protein different from the first portion, wherein the second antibody has a second affinity to bind to the second portion.

The invention relates to an immunochromatography analysis device which enables simple and rapid diagnosis of dengue virus infection, and an object thereof is to provide an immunochromatography analysis device which can reduce a cross-reaction with a virus belonging to Flaviviridae other than dengue virus and which can specifically detect dengue virus. The invention relates to an immunochromatography analysis device for detecting dengue virus including a sample application part, a labeling substance-holding part, a chromatography medium part having a detection part and an absorption part, wherein the labeling substance-holding part contains a first antibody which recognizes the amino acid sequence of SEQ ID NO: 2 that is present in the whole amino acid sequence of dengue virus NS1 of SEQ ID NO: 1, and the detection part contains a second antibody which recognizes the three-dimensional structure of dengue virus NS1.

The disclosure concerns a polypeptide suitable for detecting antibodies against Zika virus in an isolated biological sample having a Zika virus NS1 wing domain specific amino acid sequence and variants thereof, wherein no further Zika virus specific amino acid sequences are present in the polypeptide. This polypeptide does not immunologically cross-react with antibodies raised against structurally related antigens from tick-borne encephalitis virus, Dengue virus 1-4, West Nile virus, yellow fever virus or Japanese encephalitis virus, but immunologically reacts with antibodies raised against full length Zika virus NS1 antigen. Also disclosed is a method of producing a soluble and immunoreactive Zika virus NS1 polypeptide as well as methods and kits for detecting antibodies specific for Zika virus in an isolated sample.

In one aspect, provided herein are antibodies that bind to Zika virus non-structural protein 1 (NS1) and compositions comprising the same. In a specific embodiment, such antibodies or compositions thereof may be used to passively immunize a subject against Zika virus. In another embodiment, such antibodies or compositions thereof may be used to diagnose a Zika virus infection. In another aspect, provided herein are recombinant NS 1 polypeptides and compositions comprising the same that may be used to immunize a subject against Zika virus disease.

The present disclosure is directed to antibodies binding to and neutralizing Zika virus and methods for use thereof.

A system for providing colorimetric and ratiometric comparison and quantification for medical test results, comprising a testing device including an alignment target and including a plurality of immunoassay test strips, the plurality of immunoassay test strips each including a test line and a control line, and a colorimetry device configured to operate with a mobile device, the mobile device including a camera and a software application stored thereon, wherein the software application provides executable instructions to detect color properties of a color of the test line and a color of a control line of at least one of the plurality of immunoassay test strips, determine a risk value for each of at least one disease risks tested using the biologic sample, wherein the risk value is a rating determined from the color properties of the color of the test line, and provide medical test results based on the risk value.

The present disclosure relates to polypeptides that specifically bind to Dengue virus non¬structural protein 1, including antibodies and fragments thereof. The antibody or antigen-binding fragment thereof may specifically bind Dengue virus (DENV) serotype 4 and include: a heavy chain variable region that comprises at least one CDR amino acid sequence selected from the group consisting of: SGYNWH, YIH YS GGTN YNPS LKS, RTGTVPFAY, SYVMH, YLNPYNDDTKYNEKFKG, and GPPYALDY. The present disclosure further relates to methods of producing the polypeptides of the present disclosure, methods of diagnosing DENV, and methods of treating a DENV infection.

A biological sample, for example blood, serum, or plasma, is evaluated for the presence of anti-Zika virus (ZIKV) IgM- and IgG antibodies specific for ZIKV nonstructural protein 1 (NS1) by measuring the signal intensities of such antibodies in an immunoassay of the sample. Subjects are scored as being positive or negative for ZIKV infection based on the combined results of such determinations.